© 2021 BioMarin. All rights reserved.

Forbes Ranks BioMarin 12th Most Innovative Company in the World
For the fourth consecutive year, BioMarin ranks in top 20 on list
Aug 21, 2017

SAN RAFAEL, Calif., Aug. 21, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that it has been ranked 12th on Forbes magazine's 2017 list of the "World's Most Innovative Companies." BioMarin, a pharmaceutical company focused on rapidly developing and delivering first-in-class or best-in-class therapies for those with severe rare diseases, is dedicated to providing therapies for unmet medical needs.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

This is the fourth consecutive year that BioMarin has received the recognition, acknowledging the company's commitment to making an impact in the lives of small patient populations. The two previous years the company was ranked 10th and in 2014, the company ranked 7th.

"We are honored to receive this recognition from Forbes each year amongst so many notable and worthy companies," said Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin. "In 2017, we continue to advance our innovative portfolio to serve patients with rare genetic diseases, now with six therapies on the market. This year also marks the company's 20th year of making a big difference for small patient populations."

Forbes' rankings are based on the companies' 'innovation premium' which is a measure of how much investors have bid up the stock price of a company above the value of its existing businesses based on expectations of future innovative results, products, services and markets. To qualify, the businesses must have at least seven years of financial data and a market value greater than $10 billion, and have measurable investment in research and development.

To view the complete list click here.

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.




Traci McCarty

Debra Charlesworth

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.

(415) 455-7558

(415) 455-7451


SOURCE BioMarin Pharmaceutical Inc.